NCT07906496Not yet recruiting
Acceptance and Committment Therapy Combined With Ketamine in Difficult-to-Treat Depression.
Recovery-focused Acceptance and Commitment Therapy Combined With Ketamine (K-ACT) for Patients With Difficult-to-treat Depression: a Feasibility Study.
Source: ClinicalTrials.gov · Last updated 30 Oct 2026
Brief summary (registry, in English)
Ketamine is often used to treat depression where standard treatments have failed. Yet, even with ketamine, depression can persist and make it difficult to keep up with life. This study examines whether it is practical, safe and helpful to use a talk therapy (Acceptance and Commitment Therapy, ACT) in patients with difficult-to-treat depression receiving ketamine through the Ketamine Intervention Program at UBC Hospital. Researchers expect that combining ACT plus Ketamine ("K-ACT") will be feasible, safe, and will help patients functioning better in their daily lives, feeling that they are recovering, and having fewer symptoms of depression.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 18 Oct 2026
- Start date
- 1 Jan 2027
- Primary completion date
- 30 Jun 2028
- Lead sponsor
- University of British Columbia
- Diseases
- Depression
- NCT number
- NCT07906496
What you commit to
- Study type: Interventional
- Planned participants: 50
- From 1 Jan 2027 to the primary completion date, 30 Jun 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Currently undergoing non-ACT structured psychotherapy (e.g., cognitive-behavioural therapy).
Other illness
- They have: any of history of ketamine use disorder; a history of alcohol or other substance use disorder in the past 6 months; dementia or delirium; unstable medical conditions; uncontrolled hypertension; a history of seizures in the past 6 months; a history of elevated intracranial pressure/aneurysmal disease/arteriovenous malformation/intracranial hemorrhage.
- They have an allergy to ketamine.
Other
- Individuals will not be eligible for the K-ACT study if they are deemed ineligible for enrollment with the KIP at UBC Hospital due to meeting any of the following existing exclusion criteria:
- They are experiencing active psychosis.
- They are currently pregnant or breastfeeding.
- Currently undergoing ACT.
- Past ACT within last 12 months.
Who the study is looking for
- To participate in this study, individuals must be eligible for and enrolled in the Ketamine Intervention Program (KIP) at UBC Hospital, an ongoing clinical program for difficult-to-treat depression, which has the following inclusion criteria:
- Be of age 18 or older.
- Have a DSM-5-TR diagnosis of major depressive disorder (MDD) or bipolar disorder (BD), in a current major depressive episode.
- If diagnosed with MDD, have failed adequate trials of at least 2 antidepressants and 1 adjunctive medication(s); if BD, having failed adequate trials of at least 3 agents for bipolar depression.
- Have a referral from a community psychiatrist who agrees to follow the patient throughout the entire trial.
- Have the ability to provide informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UBC Hospital Coordinator of this site? Confirm its status | Vancouver | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.